Syngene International Quarterly Results for Trading Insights
In Mar 2026, Syngene International (SYNGENE) reported revenue ₹1,059 Cr and net profit ₹148 Cr — revenue +2.1% YoY. Analyse Syngene International shareholding analysis to track promoter, FII and institutional holdings.
SYNGENE Quarterly Results — Revenue, Profit & EPS Highlights
Syngene International latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View SYNGENE 52-week performance for the annual high/low range and current price position.
- Revenue of ₹1,059 Cr in Mar 2026 (+39.2% vs Jun 2026, +2.1% vs Mar 2025)
- Net Profit of ₹148 Cr in Mar 2026 (+1744.4% vs Jun 2026, -19.1% vs Mar 2025)
- EBITDA of ₹320 Cr in Mar 2026 (+210.7% vs Jun 2026)
- Operating Margin of 29.0% in Mar 2026 (+18.0pp vs Jun 2026)
- Earnings Per Share of ₹3.68 in Mar 2026 (+1772.7% vs Jun 2026)
Syngene International Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SYNGENE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,059 | 761 | 926 | 1,037 | 892 | 39.2% | 2.1% |
| Net Profit (₹ Cr) | 148 | -9 | 67 | 183 | 87 | - | - |
| EBITDA (₹ Cr) | 320 | 103 | 215 | 363 | 224 | - | - |
| EPS (₹) | 3.68 | -0.22 | 1.67 | 4.56 | 2.16 | - | - |
| Operating Margin (%) | 29.0% | 11.0% | 22.0% | 34.0% | 24.0% | - | - |
SYNGENE Share Price Trend — 1-Year Movement Across Quarterly Results
Syngene International 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Syngene International share price chart.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SYNGENE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Syngene International latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores